ABILIFY MAINTENA is an extended-release injectable aripiprazole prescription medication used for the treatment of schizophrenia and bipolar I disorder in adults.
ABILIFY MAINTENA (aripiprazole) is an extended-release injectable prescription medication that must be administered by a healthcare professional. It is indicated for the treatment of schizophrenia and as a maintenance monotherapy treatment for bipolar I disorder in adults. Manufactured by Otsuka America Pharmaceutical, Inc., ABILIFY MAINTENA is administered as a once-monthly intramuscular injection in either the deltoid or gluteal muscle.
Patients and healthcare providers can reference complete prescribing information, medication guides, and instructions for use to understand dosage adjustments, administration procedures, potential adverse reactions, and specific considerations for different patient populations.
Nuutste handleidings van manuals+ saamgestel vir hierdie handelsmerk.
Algemene vrae oor handleidings, registrasie en ondersteuning vir hierdie handelsmerk.
It is indicated for the treatment of schizophrenia in adults and for maintenance monotherapy treatment of bipolar I disorder in adults.
The recommended dose is typically 400 mg administered as a monthly intramuscular injection (no sooner than 26 days after the previous injection) by a healthcare professional.
It is manufactured by Otsuka America Pharmaceutical, Inc.
You can find the full prescribing information, detailed instructions for use, and medication guides right here on our page or on the official manufacturer webwebwerf.
You can report suspected adverse reactions to Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.